Kovack Advisors, Inc. Halozyme Therapeutics, Inc. Transaction History

Kovack Advisors, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 01, 2018	SELL	$16.87 - $20.3 $214,232 - $257,789	-12,699 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$17.06 - $21.2 $88,626 - $110,134	-5,195 Reduced 29.03%	12,699 $479,000
Q4 2017 May 15, 2018	SELL	$16.75 - $20.8 $10,050 - $12,480	-600 Reduced 3.24%	17,894 $363,000
Q4 2017 Feb 01, 2018	BUY	$16.75 - $20.8 $125,625 - $156,000	7,500 Added 68.22%	18,494 $375,000
Q3 2017 Aug 02, 2018	SELL	$11.76 - $17.4 $50,568 - $74,820	-4,300 Reduced 28.12%	10,994 $191,000
Q2 2017 Aug 30, 2018	BUY	N/A	15,294	15,294 $196,000

542

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.35B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Kovack Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Kovack Advisors, Inc. with notifications on news.